Most Viewed Videos

Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide

Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial

Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Rowan T. Chlebowski, MD, PhD, on Weight Loss and Breast Cancer Risk: Results From the Women’s Health Initiative

Mihir M. Kamdar, MD, on Managing Cancer-Related Pain With Artificial Intelligence

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”

Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Oct

Today In Oncology

The Future of the Radiation Abscopal Response

Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater

Exercise for Patients With Cancer to Minimize Treatment Cardiotoxicity

FDA Pipeline Designations for Acute GVHD, PTCL

Patient Preference for More vs Less Medical Care for Thyroid Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2016 Guidelines

As My Outside World Became Smaller, My Family Focus Became Larger

Romiplostim for Patients With Chemotherapy-Induced Thrombocytopenia

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer

Pooled Analysis of Outcomes in Older Women With Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Plus Aromatase Inhibitor Therapy

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Olaparib/Enzalutamide/Abiraterone

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide

Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial

Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Rowan T. Chlebowski, MD, PhD, on Weight Loss and Breast Cancer Risk: Results From the Women’s Health Initiative

Mihir M. Kamdar, MD, on Managing Cancer-Related Pain With Artificial Intelligence

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab

Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”

Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

The Future of the Radiation Abscopal Response

Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater

Exercise for Patients With Cancer to Minimize Treatment Cardiotoxicity

FDA Pipeline Designations for Acute GVHD, PTCL

Patient Preference for More vs Less Medical Care for Thyroid Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2016 Guidelines

As My Outside World Became Smaller, My Family Focus Became Larger

Romiplostim for Patients With Chemotherapy-Induced Thrombocytopenia

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer

Pooled Analysis of Outcomes in Older Women With Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Plus Aromatase Inhibitor Therapy

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial